Personal information

No personal information available

Activities

Collapse all

Employment (1)

Xiangya Hospital Central South University: Changsha, CN

(Oncology)
Employment
Source: Self-asserted source
Shan Zeng

Education and qualifications (1)

Xiangya Hospital Central South University: Changsha, Hunan, CN

Education
Source: Self-asserted source
Shan Zeng

Funding (1)

Molecular mechanisms of m6A demethylation-mediated tRNAVal-derived tRF-RNA3008A combining with Ago2 protein on the proliferation and metastasis inhibition of colon cancer

Grant
National Natural Science Foundation of China (Beijing, CN)
GRANT_NUMBER: 81974384
Source: Self-asserted source
Shan Zeng

Works (9)

Converting "cold" to "hot": epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells.

Cancer communications (London, England)
2024-05-07 | Journal article | Author
DOI: 10.1002/cac2.12546
PMID: 38715348
PMC: PMC11194457
Contributors: Tang Y; Cui G; Liu H; Han Y; Cai C; Ziyang Feng; Shen H; Shan Zeng
Source: Self-asserted source
Shan Zeng

The functional and clinical roles of liquid biopsy in patient-derived models.

Journal of hematology & oncology
2023-04-08 | Journal article
DOI: 10.1186/s13045-023-01433-5
PMID: 37031172
PMC: PMC10082989
Contributors: Zhu Z; Hu E; Shen H; Tan J; Zeng S
Source: Self-asserted source
Shan Zeng

The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy.

Frontiers in pharmacology
2022-09-30 | Journal article
DOI: 10.3389/fphar.2022.1015510
PMID: 36249804
PMC: PMC9561342
Contributors: Cai C; Luo Q; Liu Y; Peng Y; Zhang X; Jiang Z; Feng Z; Qi Y; Gao Y; Liu Y et al.
Source: Self-asserted source
Shan Zeng

Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism.

International journal of biological sciences
2022-07-04 | Journal article
DOI: 10.7150/ijbs.71134
PMID: 35864952
PMC: PMC9295067
Contributors: Fu Y; Liu S; Robim M Rodrigues; Han Y; Guo C; Zhu Z; Yong He; Mackowiak B; Feng D; Gao B et al.
Source: Self-asserted source
Shan Zeng
grade
Preferred source (of 2)‎

Identification of tumour immune infiltration-associated snoRNAs (TIIsno) for predicting prognosis and immune landscape in patients with colon cancer via a TIIsno score model.

EBioMedicine
2022-02-07 | Journal article
DOI: 10.1016/j.ebiom.2022.103866
PMID: 35144219
PMC: PMC8844792
Contributors: Cai C; Peng Y; Shen E; Wan R; Gao L; Gao Y; Yulai Zhou; Huang Q; Chen Y; Liu P et al.
Source: Self-asserted source
Shan Zeng

tRF3008A suppresses the progression and metastasis of colorectal cancer by destabilizing FOXK1 in an AGO-dependent manner.

Journal of experimental & clinical cancer research : CR
2022-01-22 | Journal article
DOI: 10.1186/s13046-021-02190-4
PMID: 35065674
PMC: PMC8783529
Contributors: Han Y; Peng Y; Liu S; Wang X; Cai C; Guo C; Chen Y; Gao L; Huang Q; He M et al.
Source: Self-asserted source
Shan Zeng

A comprehensive analysis of the efficacy and safety of COVID-19 vaccines.

Molecular therapy : the journal of the American Society of Gene Therapy
2021-08-06 | Journal article
DOI: 10.1016/j.ymthe.2021.08.001
PMID: 34365034
PMC: PMC8342868
Contributors: Cai C; Peng Y; Shen E; Huang Q; Chen Y; Liu P; Guo C; Feng Z; Gao L; Zhang X et al.
Source: Self-asserted source
Shan Zeng

A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy.

Aging
2020-09-24 | Journal article
DOI: 10.18632/aging.104058
PMID: 32973124
PMC: PMC7585129
Contributors: Cai C; Tang D; Han Y; Shen E; Omar Abdihamid; Guo C; Shen H; Zeng S
Source: Self-asserted source
Shan Zeng

MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her-2/PI3K/AKT Signaling.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2020-05-26 | Journal article | Author
DOI: 10.1002/advs.202000112
PMID: 32670759
PMC: PMC7341094
Contributors: Han Y; Peng Y; Fu Y; Cai C; Guo C; Liu S; Li Y; Chen Y; Shen E; Long K et al.
Source: Self-asserted source
Shan Zeng

Peer review (2 reviews for 2 publications/grants)

Review activity for Advanced science. (1)
Review activity for iScience. (1)
How many people are using ORCID?